IOVA Iovance Biotherapeutics Inc.

+0.53  (+2%)
Previous Close 23.91
Open 24.18
Price To Book 6.94
Market Cap 3,018,687,806
Shares 123,514,231
Volume 595,099
Short Ratio
Av. Daily Volume 2,241,907

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiated March 2017. Poster session at SITC November 10, 2017. Data released January 24, 2018 showed 3/8 PRs.
Head and neck cancer
Phase 2 updated data noted ORR 38 percent (2 CRS; 23 PRs). BLA filing due 2H 2020.
LN-144 - lifileucel
Refractory metastatic melanoma
Phase 2 update due at ASCO June 1, 2019, 8am. Data released May 31, 2019 noted ORR 44%; CR 11%. BLA filing due 2H 2020.
Cervical cancer

Latest News

  1. Does Market Volatility Impact Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) Share Price?
  2. Here's Why Iovance Biotherapeutics Soared 50% in June
  3. Iovance stock up 2% after company gives positive regulatory update on potential cervical cancer treatment
  4. Iovance Biotherapeutics Provides Cervical Cancer Program Updates Following End of Phase 2 Meeting with U.S. Food and Drug Administration (FDA)
  5. 3 Stocks With a Perfect Smart Score
  6. 3 Top Healthcare Stocks to Buy Right Now
  7. Harry Boxer’s three biotech stocks on the move include Nektar Therapeutics
  8. Cancer Therapy Stocks Soar After Pfizer Deal
  9. Shares of cancer-therapy companies skyrocket after Pfizer acquisition news
  10. Why Iovance Biotherapeutics Stock Jumped Today
  11. Did Hedge Funds Drop The Ball On Iovance Biotherapeutics, Inc. (IOVA) ?
  12. PHIO: Two Compounds Entering Clinic in 2020
  13. Iovance Biotherapeutics Appoints Athena Countouriotis, M.D., to Board of Directors
  14. Cancer-Fighting Stocks & ETF: What You Need to Know
  15. Iovance and Amgen Are Making Cancer History
  16. Why Cancer-Fighting Stocks & ETFs Are Soaring
  17. Oncology Stock Expected to Double (Again)
  18. Updated Results of Studies in Advanced Cervical Cancer and Melanoma Support Long-Term Efficacy of Iovance Tumor Infiltrating Lymphocyte (TIL) Therapy
  19. Iovance Biotherapeutics to Participate in Upcoming Conferences in June